# A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

> **NCT01626573** · PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 106 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Itacitinib Placebo

## Key facts

- **NCT ID:** NCT01626573
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-10
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2019-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01626573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01626573, "A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01626573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*